Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating Expenses        
Research and development $ 1,151,740 $ 3,136,838 $ 4,478,793 $ 8,319,907
General and administrative 1,015,872 2,920,280 4,508,818 6,137,674
Operating Loss (2,167,612) (6,057,118) (8,987,611) (14,457,581)
Other Income (Expense)        
Interest income, net 85,661 36,708 271,022 45,672
Net Loss $ (2,081,951) $ (6,020,410) $ (8,716,589) $ (14,411,909)
Net Loss per Common Share - Basic $ (0.08) $ (0.37) $ (0.34) $ (0.90)
Net Loss per Common Share - Diluted $ (0.08) $ (0.37) $ (0.34) $ (0.90)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic 27,002,908 16,200,222 25,585,222 15,991,653
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted 27,002,908 16,200,222 25,585,222 15,991,653